They observed significant diagnostic sensitivity of neopterin testing to detect human immunodeficiency virus (HIV) infection prior to seroconversion, which was comparable to p24 screening but no longer helpful when viral nucleic acid amplification (NAT) technologies are applied. However, neopterin determination failed to detect hepatitis Β and C viruses (HBV and HCV) in the window period. In the Austrian Tyrol, additional neopterin screening was introduced in 1986 with the goal to reduce transmission of acute virus infections (2). This was related to lessons learned from the initial HIV epidemic that blood transfusion cannot escape from newly emerging and/or recognized infections as long as specific testing is solely performed. Additional non-specific screening using immune response markers like neopterin would represent a valid option to reduce this risk. In 1994 nationwide screening for elevated neopterin concentrations was introduced in whole Austria, and donations with neopterin concentrations outside the 98th percentile are discarded. One of the major goals of this non-specific screening strategy is to build a kind of umbrella against virus infections which are not routinely screened for. As mentioned in the article, specific IgM testings for acute cytomegalovirus, Epstein Barr virus and parvovirus Β19 infection showed that indeed the frequency of these infections is significantly higher in the group of donors with neopterin concentrations outside the cut-off used as compared with those donors within normal. Even if they are supposed to do not too much harm to the normal population, they can have deleterious effects in immunocompromized transfusion recipients. Also in HCV seropositive donors, a positive per result was significantly more often present in donations with neopterin concentrations above the cutoff (3). Since neopterin has been performed in the Austrian Tyrol as early as 1986, one can estimate that this screening program has reduced HCV transmission rates by a factor of seven throughout several years until HCV screening was introduced. Nevertheless, according to the data of Nübling et al., neopterin screenings fails to detect early phase of HCV infections. However, recent data further support the concept that neopterin screening should be able to detect a wide range of acute virus infections, and thus, also newly emerging virus infections should be detectable by elevated neopterin concentrations, e.g., highly elevated neopterin concentrations were observed in patients suffering from acute SARS (4) and dengue virus infection (5). Some 25 years ago, the newly recognized AIDS-epidemic has shown the limitation of current strategies to guarantee virus safety of blood donations. As long as specific testing is solely performed, blood transfusion cannot control for newly emerging and/or recognized infections. Additional non-specific screening using immune response markers like neopterin could represent a valid option to reduce this risk.
To the Editor:
NUbling and coworkers from the Paul Ehrlich Institute in Frankfurt am Main, Germany, presented data on the sensitivity of neopterin to detect acute infection in the window-phase before detectable antibody seroconversion (1 ). They observed significant diagnostic sensitivity of neopterin testing to detect human immunodeficiency virus (HIV) infection prior to seroconversion, which was comparable to p24 screening but no longer helpful when viral nucleic acid amplification (NAT) technologies are applied. However, neopterin determination failed to detect hepatitis Β and C viruses (HBV and HCV) in the window period. In the Austrian Tyrol, additional neopterin screening was introduced in 1986 with the goal to reduce transmission of acute virus infections (2) . This was related to lessons learned from the initial HIV epidemic that blood transfusion cannot escape from newly emerging and/or recognized infections as long as specific testing is solely performed. Additional non-specific screening using immune response markers like neopterin would represent a valid option to reduce this risk. In 1994 nationwide screening for elevated neopterin concentrations was introduced in whole Austria, and donations with neopterin concentrations outside the 98th percentile are discarded. One of the major goals of this non-specific screening strategy is to build a kind of umbrella against virus infections which are not routinely screened for. As mentioned in the article, specific IgM testings for acute cytomegalovirus, Epstein Barr virus and parvovirus Β19 infection showed that indeed the frequency of these infections is significantly higher in the group of donors with neopterin concentrations outside the cut-off used as compared with those donors within normal. Even if they are supposed to do not too much harm to the normal population, they can have deleterious effects in immunocompromized transfusion recipients. Also in HCV seropositive donors, a positive per result was significantly more often present in donations with neopterin concentrations above the cutoff (3). Since neopterin has been performed in the Austrian Tyrol as early as 1986, one can estimate that this screening program has reduced HCV transmission rates by a factor of seven throughout several years until HCV screening was introduced. Nevertheless, according to the data of Nübling et al., neopterin screenings fails to detect early phase of HCV infections. However, recent data further support the concept that neopterin screening should be able to detect a wide range of acute virus infections, and thus, also newly emerging virus infections should be detectable by elevated neopterin concentrations, e.g., highly elevated neopterin concentrations were observed in patients suffering from acute SARS (4) and dengue virus infection (5). Some 25 years ago, the newly recognized AIDS-epidemic has shown the limitation of current strategies to guarantee virus safety of blood donations. As long as specific testing is solely performed, blood transfusion cannot control for newly emerging and/or recognized infections. Additional non-specific screening using immune response markers like neopterin could represent a valid option to reduce this risk.
